COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration authorized the emergency use of a new over-the-counter COVID-19 antigen test. Unlike most antigen tests for at-home use, the new test does not require serial testing, FDA said.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Oct. 1 announced that it will meet later this month for a pair of significant discussions on COVID-19 vaccines.
Fall Preceptorship Session One: Explains how health care professionals can collaborate by embracing complementary roles within a team.
Adults with a disability are more likely than adults without one to report difficulty getting a COVID-19 vaccine, the Centers for Disease Control and Prevention reported.
The Centers for Disease Control and Prevention urged clinicians to educate pregnant patients about the benefits and safety of COVID-19 vaccination; and encourage and offer vaccination to patients who are pregnant, recently pregnant or might become pregnant to increase vaccination rates in this…
The AHA, American Medical Association and American Nurses Association applauded the recent decision by the Food and Drug Administration and Centers for Disease Control and Prevention to allow access to a Pfizer COVID-19 vaccine booster dose for nurses, physicians and others working in health care…
Data from the nation’s initial set of patients receiving COVID-19 booster shots found similar rates and types of adverse reactions, such as pain at the injection site, headache or fatigue, according to a Centers for Disease Control and Prevention study.
The Centers for Medicare & Medicaid Services announced that the agency will pay for Medicare beneficiaries’ booster doses, without cost sharing.
The Centers for Disease Control and Prevention early Friday morning opted for a broad endorsement of Pfizer COVID-19 vaccine booster shots, issuing interim guidance that recommends boosters for many vaccinated individuals, including those in high-risk occupational and institutional settings.
The Food and Drug Administration today required certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test’s performance and update the labeling for the product accordingly.